Allogene Therapeutics Ownership | Who Owns Allogene Therapeutics?
Allogene Therapeutics Ownership Summary
Allogene Therapeutics is owned by 84.01% institutional investors, 17.45% insiders. Fmr is the largest institutional shareholder, holding 11.36% of ALLO shares. American Funds SMALLCAP World A is the top mutual fund, with 5.10% of its assets in Allogene Therapeutics shares.
ALLO Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Allogene Therapeutics | 84.01% | 17.45% | -1.46% |
| Sector | Healthcare Stocks | 487.91% | 11.08% | -398.99% |
| Industry | Biotech Stocks | 307.10% | 11.11% | -218.21% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Fmr | 23.77M | 11.36% | $50.63M |
| Pfizer | 22.03M | 10.06% | $24.90M |
| Blackrock | 16.45M | 9.72% | $38.32M |
| Tpg gp a | 18.72M | 8.95% | $39.87M |
| Blackrock funding, inc. /de | 17.90M | 8.18% | $20.22M |
| Lynx1 capital management lp | 10.87M | 5.20% | $23.16M |
| Capital world investors | 11.15M | 5.09% | $12.60M |
| Vanguard group | 8.00M | 3.82% | $17.04M |
| State street | 7.25M | 3.47% | $15.44M |
| Primecap management co/ca/ | 5.72M | 2.61% | $6.46M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Lynx1 capital management lp | 10.87M | 8.68% | $23.16M |
| Vida ventures advisors | 1.80M | 7.59% | $2.23M |
| Pfizer | 22.03M | 4.32% | $24.90M |
| Wildcat capital management | 2.92M | 1.85% | $3.12M |
| Foresite capital management vi | 2.88M | 1.83% | $3.25M |
| Patient square capital lp | 2.63M | 1.07% | $2.98M |
| Tpg gp a | 18.72M | 0.64% | $39.87M |
| Dafna capital management | 1.38M | 0.43% | $1.56M |
| Frazier life sciences management | 3.87M | 0.17% | $4.37M |
| Gilead sciences | 1.16M | 0.16% | $2.46M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Blackrock | 16.45M | 0.00% | 6.79M |
| Lynx1 capital management lp | 10.87M | 8.68% | 4.67M |
| Gilead sciences | 1.16M | 0.16% | 1.16M |
| Jacobs levy equity management | 878.96K | 0.01% | 878.96K |
| Dimensional fund advisors lp | 3.56M | 0.00% | 831.15K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Fmr | 23.77M | 0.00% | -6.25M |
| Boxer capital | - | - | -3.85M |
| Perceptive advisors | - | - | -2.73M |
| Exoduspoint capital management, lp | - | - | -1.63M |
| Vestal point capital, lp | - | - | -1.50M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Gilead sciences | 1.16M | 0.16% | 1.16M | $2.46M |
| Jacobs levy equity management | 878.96K | 0.01% | 878.96K | $2.05M |
| Australiansuper pty | 382.14K | 0.00% | 382.14K | $473.86K |
| Nwi management lp | 100.00K | 0.01% | 100.00K | $113.00K |
| Acadian asset management | 70.47K | 0.00% | 70.47K | $79.00K |
Sold Out
| Holder | Change |
|---|---|
| Capital performance advisors llp | -41.00 |
| Dunhill financial | -70.00 |
| Parallel advisors | -114.00 |
| Private wealth management group | -140.00 |
| Bell investment advisors | -161.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2025 | 160 | -6.98% | 183,929,908 | -6.69% | 84 | 1.00% | 66 | -27.47% | 47 | 14.63% |
| Mar 31, 2025 | 170 | -1.73% | 196,870,758 | 4.48% | 91 | 1.13% | 90 | -2.17% | 41 | - |
| Dec 31, 2024 | 165 | 5.10% | 185,488,005 | 12.84% | 88 | 1.44% | 89 | 27.14% | 40 | -11.11% |
| Sep 30, 2024 | 156 | -8.77% | 164,386,704 | -0.47% | 78 | 0.82% | 71 | -24.47% | 45 | 9.76% |
| Jun 30, 2024 | 171 | 7.55% | 165,168,429 | 25.95% | 97 | 1.62% | 94 | 23.68% | 41 | -4.65% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| American Funds SMALLCAP World A | 11.15M | 5.10% | -1.12M |
| Fidelity Growth Compy Commingled Pl O | 4.58M | 2.19% | - |
| Vanguard US Total Market Shares ETF | 4.34M | 2.00% | - |
| Vanguard Total Stock Mkt Idx Inv | 4.19M | 1.90% | -92.41K |
| Fidelity Select Health Care | 4.00M | 1.88% | -350.00K |
| SPDR® S&P Biotech ETF | 3.90M | 1.84% | -23.78K |
| Fidelity Series Small Cap Opps | 3.54M | 1.69% | -141.30K |
| Vanguard Capital Opportunity Inv | 3.56M | 1.63% | 600.00K |
| iShares Russell 2000 ETF | 3.58M | 1.61% | - |
| T. Rowe Price Health Sciences | 2.72M | 1.23% | -30.52K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Oct 21, 2025 | Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | Sell | $46.17K |
| Jun 10, 2025 | MESSEMER DEBORAH M. | - | Sell | $52.38K |
| Apr 21, 2025 | Yoshiyama Annie | SVP, Finance | Sell | $13.54K |
| Mar 14, 2025 | Chang David D | President and CEO | Sell | $91.47K |
| Mar 14, 2025 | Beneski Benjamin Machinas | SVP, Chief Technical Officer | Sell | $10.84K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q4 | - | 1 |
| 2025 Q2 | - | 2 |
| 2025 Q1 | - | 9 |
| 2024 Q4 | - | 2 |
| 2024 Q3 | - | - |
ALLO Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools